Charles River Laboratories
2Q Revenues: $341.2 million (+16%)
2Q Earnings: $35.3 million (+29%)
YTD Revenues: $640.5 million (+8%)
YTD Earnings: $67.5 million (+28%)
Comments: Revenue for the Research Models and Services (RMS) segment was $133.1 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenue was $142.6 million, up 33% in quarter driven by the acquisition of Argenta and BioFocus, which contributed 22% to DSA revenue. Revenue for the Manufacturing segment was $65.4 million in the quarter, up 18% with growth across all businesses, including a double-digit growth rate for both the Endotoxin and Microbial Detection, and Biologics Testing Solutions businesses.